Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01287845 · ClinicalTrials.gov registry record · Phase 1
PET/CT (Positron Emission Tomography/Computed Tomography) Imaging for Safety and Tolerability and Diagnostic Performance of BAY1075553 in Patients With Prostate Cancer and Healthy Volunteers
A Phase 1 study of Diagnostic Imaging, sponsored by Life Molecular Imaging.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 2
- Study locations
NCT01287845 is a Phase 1 study of Diagnostic Imaging that has completed, run by Life Molecular Imaging. The registered enrollment target is 14 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT01287845, a Phase 1 study of Diagnostic Imaging, has completed, sponsored by Life Molecular Imaging.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 2
- Study locations
Study Summary
PET/CT imaging study for evaluation of safety and tolerability and diagnostic performance of BAY1075553 in patients with prostate cancer and in healthy volunteers
Conditions Studied
Interventions
- DRUG BAY1075553
Study Locations (2)
Michigan
- - Ann Arbor
Other
- - Linz
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2011-02 |
| Est. Completion | 2011-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01287845
The ClinicalTrials.gov registry entry for NCT01287845 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Life Molecular Imaging, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diagnostic Imaging appearing as the primary indexed condition, and to 1 intervention - of which BAY1075553 is the first listed.
NCT01287845 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Michigan, Other.
Frequently Asked Questions
What is clinical trial NCT01287845 about?
NCT01287845 is a clinical study titled "PET/CT (Positron Emission Tomography/Computed Tomography) Imaging for Safety and Tolerability and Diagnostic Performance of BAY1075553 in Patients With Prostate Cancer and Healthy Volunteers". PET/CT imaging study for evaluation of safety and tolerability and diagnostic performance of BAY1075553 in patients with prostate cancer and in healthy volunteers
What is the current status of trial NCT01287845?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2011-02. Estimated completion is 2011-11.
What conditions does trial NCT01287845 study?
This clinical trial studies the following conditions: Diagnostic Imaging.
What interventions are being tested in trial NCT01287845?
The interventions under investigation include: BAY1075553 (DRUG).
Who is sponsoring clinical trial NCT01287845?
This trial is sponsored by Life Molecular Imaging, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01287845 being conducted?
This trial has 2 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diagnostic Imaging
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.